Table 3.
Clinical trials of second-line chemotherapy for pancreatic cancer.
| Trial | Regimen | n | Response Rate | Median PFS | Median OS | Hazard Ratio (95% CI) | P-value | Author (Year) |
|---|---|---|---|---|---|---|---|---|
| CONKO-03 | Best supportive care | 23 | NA | NA | 2.3 months | 0.45 | 0.008 | Pelzer (2011) [29] |
| OFF | 23 | NA | NA | 4.8 months | (0.24–0.83) | |||
| CONKO-03 | FF | 91 | NA | 2.1 months | 3.0 months | NA | 0.014 | Pelzer (2008) [30] |
| OFF | 77 | NA | 3.0 months | 6.0 months | ||||
| PANCREOX | FF | 54 | 8.5% | 2.9 months | 9.9 months | 1.78 | 0.024 | Gill S (2016) [31] |
| FOLOX | 54 | 13.2% | 3.1 months | 6.1 months | (1.08–2.93) | |||
| - | S-1 | 135 | 11.5% | 2.8 months | 6.9 months | 1.03 | 0.82 | Ohkawa S (2015) [32] |
| SOX | 136 | 20.9% | 3.0 months | 7.4 months | (0.79–1.34) | |||
| - | S-1 | 67 | 6.0% | 1.9 months | 5.8 months | 0.75 | 0.13 | Ioka T (2017) [33] |
| IRIS | 60 | 8.3% | 3.5 months | 6.8 months | (0.51–1.09) | |||
| GRAPE | S-1 | 290 | 19.7% | 2.8 months | 7.9 months | 0.98 | 0.756 | Ioka T (2019) [34] |
| TAS118 | 296 | 27.5% | 3.9 months | 7.6 months | (0.82–1.16) | |||
| NAPOLI-1 | Fluorouracil/folinic acid/nanoliposomal irinotecan | 117 | 16% | 3.1 months | 6.1 months | 0.67 | 0.012 | Wang-Gillam A (2016) [35] |
| Fluorouracil/folinic acid | 119 | 1% | 1.5 months | 4.2 months | (0·49–0·92) | |||
| Nanoliposomal irinotecan | 151 | 6% | 2.7 months | 4.9 months | - | - |
PFS, Progression-free survival; OS, overall survival; OFF, oxaliplatin/fluorouracil/folinic acid; FF, fluorouracil/folinic acid; FOLOX, fluorouracil/Leucovorin/oxaliplatin; SOX, S-1/oxaliplatin; IRIS, irinotecan/S-1; TAS118, S-1/leucovorin.